Literature DB >> 7535594

CD40 ligand triggered interleukin-6 secretion in multiple myeloma.

M Urashima1, D Chauhan, H Uchiyama, G J Freeman, K C Anderson.   

Abstract

Previous studies have suggested that interleukin-6 (IL-6) may mediate growth of multiple myeloma (MM) in either an autocrine or paracrine growth mechanism. However, those molecules which can trigger IL-6 secretion either by tumor cells or non-MM marrow cells are not well characterized. In the present study, we have examined the expression and functional significance of CD40 on MM and plasma cell leukemia (PCL) cells and derived cell lines, as well as long-term bone marrow stromal cells (BMSCs) and derived cell lines. CD40 was expressed on the majority of MM cells (> 90%) and BMSCs (> 70%). Triggering via CD40 using NIH3T3 CD40 ligand transfectant (CD40LT) cells increased (> 30%) cell surface CD80, CD18, CD11a, CD11b, and CD11c expression on MM cell lines. Culture with either fresh or paraformaldehyde fixed NIH3T3 CD40LT cells upregulates IL-6 secretion in MM cells and MM-derived cell lines, as well as normal and MM bone marrow mononuclear cells (BMMCs), BMSCs, and BMSC lines; this effect can be specifically blocked by anti-CD40 monoclonal antibody (MoAb). BMMCs and BMSCs from patients with MM secreted significantly more IL-6 than those from healthy donors (n = 3, P < .001); moreover, after stimulation using CD40L, IL-6 secretion was fourfold greater (n = 3, P < .001) from MM BMMCs and BMSCs than from normal BMMCs and BMSCs. Myeloma (CD38+CD45RA-) cells and non-MM (CD38+CD45RA+, CD38-CD45RA+, and CD38-CD45RA-) BMMCs were separated by dual fluorescence cell sorting. The latter secreted fourfold more IL-6 than the former (n = 2, P < .001). Increased IL-6 secretion (up to 28-fold) and proliferation (Stimulation index 10) by CD38+CD45RA-MM cells was triggered by culture with NIH3T3 CD40LT cells. Finally, anti-CD40MoAb partially (30%) blocked tumor cell to BMSC adhesion-induced IL-6 secretion. These studies support the view that CD40L may trigger IL-6 secretion by both MM cells and BMSCs and that IL-6-mediated autocrine and paracrine growth mechanisms may be possible in MM.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535594

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

2.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

3.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.

Authors:  Pradeep Bangalore-Prakash; Laura L Stunz; Nurbek Mambetsariev; Amy L Whillock; Bruce S Hostager; Gail A Bishop
Journal:  Blood Adv       Date:  2017-12-18

Review 6.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

7.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  Generation of human CD40-activated B cells.

Authors:  Tanja M Liebig; Anne Fiedler; Shahram Zoghi; Alexander Shimabukuro-Vornhagen; Michael S von Bergwelt-Baildon
Journal:  J Vis Exp       Date:  2009-10-16       Impact factor: 1.355

9.  BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

Authors:  Danielle T Avery; Susan L Kalled; Julia I Ellyard; Christine Ambrose; Sarah A Bixler; Marilyn Thien; Robert Brink; Fabienne Mackay; Philip D Hodgkin; Stuart G Tangye
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

10.  Identification and characterisation of malignant cells using RT-PCR on single flow-sorted cells.

Authors:  T Rasmussen; L Honoré; H E Johnsen
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.